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ABSTRACT
Background: Immunotherapy targeting cancer-testis antigen NY-ESO-1 shows 
promise for tumors with poor response to chemoradiation. Malignant peripheral nerve 
sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few 
effective treatment options. 
Materials Methods: Using a comprehensive tissue microarray (TMA) of both benign 
and malignant tumors in primary, recurrent, and metastatic samples, we examined 
NY-ESO-1 expression in peripheral nerve sheath tumor (PNST) and adipocytic tumors. 
The PNST TMA included 42 MPNSTs (spontaneous n = 26, NF1-associated n = 16), 
35 neurofibromas (spontaneous n = 22, NF-1 associated n = 13), 11 schwannomas, and 18 
normal nerves. The LPS TMA included 48 well-differentiated/dedifferentiated (WD/DD)  
LPS, 13 myxoid/round cell LPS, 3 pleomorphic LPS, 8 lipomas, 1 myelolipoma, and 
3 normal adipocytic tissue samples. Stained in triplicate, NY-ESO-1 intensity and 
density were scored. 
Results: NY-ESO-1 expression was exclusive to malignant tumors. 100% of 
myxoid/round cell LPS demonstrated NY-ESO-1 expression, while only 6% of WD/
DD LPS showed protein expression, one of which was WD LPS. Of MPNST, 4/26 (15%) 
spontaneous and 2/16 (12%) NF1-associated MPNSTs demonstrated NY-ESO-1 
expression. Strong NY-ESO-1 expression was observed in myxoid/round cell and 
dedifferentiated LPS, and MPNST in primary, neoadjuvant, and metastatic settings. 
Conclusions: We found higher prevalence of NY-ESO-1 expression in MPNSTs 
than previously reported, highlighting a subset of MPNST patients who may benefit 
from immunotherapy. This study expands our understanding of NY-ESO-1 in WD/DD 
LPS and is the first demonstration of staining in a WD LPS and metastatic/recurrent 
myxoid/round cell LPS. These results suggest immunotherapy targeting NY-ESO-1 
may benefit patients with aggressive tumors resistant to conventional therapy.
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INTRODUCTION
Targeted immunotherapy presents an opportunity 
to overcome chemotherapeutic resistance in several 
human cancers. Cancer-testis antigen NY-ESO-1 (New 
York esophageal squamous cell carcinoma 1), encoded 
by the CTAG 1B gene, has quickly evolved into a vaccine 
and immunotherapy candidate since its identification in 
the late 1990’s. Initially detected in the serum of patients 
with esophageal squamous carcinoma [1], NY-ESO-1 is 
present in fetal and adult germ cells and is not detectable 
in somatic tissues (excluding insignificant expression in 
brain, thymic, uterine and placental tissue), making it an 
attractive cancer immunotherapy target [2]. An appealing 
feature of NY-ESO-1 is its ability to elicit spontaneous 
antibody and T-cell responses in certain cancer subtypes. 
Currently, NY-ESO-1 is the focus of adoptive cellular 
therapy and vaccine trials for melanoma, sarcoma, multiple 
myeloma, non-small cell lung carcinoma, and urothelial, 
esophageal, ovarian, and prostatic neoplasms [3–5]. 
Amongst sarcomas, synovial sarcomas and myxoid/
round cell liposarcomas frequently express NY-ESO-1. 
Recently, Robbins et al. published an adoptive therapy 
trial using retrovirally transfected, NY-ESO-1–specific 
T-cell receptor, and documented clinical responses in 
66% of patients with synovial sarcoma [6]. However, to 
date, limited numbers of peripheral nerve sheath tumors 
(PNSTs) and non-myxoid/round cell liposarcomas (LPS) 
have been tested. Malignant peripheral nerve sheath 
tumors (MPNST), in particular, portend a poor patient 
prognosis and show limited response to traditional 
chemoradiation [7–11]. Therefore, investigation into 
synergistic therapies is warranted.
The purpose of this study was to characterize the 
prevalence and intensity of NY-ESO-1 in PNSTs and 
adipocytic neoplasms. In order to include large numbers 
of different tumor subtypes, as well as primary, locally 
recurrent, and metastatic tumors, we utilized previously 
constructed tissue microarrays (TMAs) of PNSTs and 
adipocytic tumors from our institution. To our knowledge, 
this is the first report that specifically evaluates NY-ESO-1 
expression in primary, recurrent, and metastatic MPNSTs 
and LPS. This is also the first demonstration of differential 
staining in spontaneous and NF1-associated PNSTs, and in 
benign neurofibromas.
RESULTS 
Strong NY-ESO-1 expression was observed in 
samples of myxoid/round cell LPS, dedifferentiated LPS, 
and MPNST in primary, neoadjuvant, and metastatic settings 
(See Table 1, Table 2).
Lipomatous tumors
All thirteen patients (100%) with myxoid/round 
cell liposarcoma exhibited strikingly uniform, moderate 
to intense (2–3+) NY-ESO-1 expression with a clean 
background devoid of artefactual staining (Table 2). 
Eleven of these thirteen cases were primary tumors. 
All primary tumors (11/11) demonstrated moderate to 
intense (2–3+) positivity which was diffuse (> 75% 
of tumor cases). Three of the primary myxoid/round 
cell liposarcoma cases had received neoadjuvant 
chemotherapy; all post-treatment tumors showed diffuse, 
strong staining for NY-ESO-1. A representative example 
of a primary myxoid/round cell liposarcoma and its 
staining pattern are shown in Figure 1A and 1B. 
Four patients with myxoid/round cell liposarcoma 
had multiple tumors, i.e. both primary and recurrent and/
or metastatic tumors from the same patient represented on 
the TMA [patients #10, 33, 54, 71]. These 4 patients had 
a total of eight recurrent or metastatic tumors. All eight 
tumors continued to display moderate to strong (2–3+) 
staining intensity, similar to their primary tumors. One 
patient (#33) exhibited an increase in the percentage of 
NY-ESO-1 positive tumor cells in the recurrent/metastatic 
tumors from focal (< 25% of tumor cells) to diffuse 
(> 75% of tumor cells) (Table 3) (Figure 1H). Staining 
in recurrent and metastatic tumors generally showed 
similar or an increased intensity or density of staining as 
compared to the primary tumor (Table 3).
Among the well differentiated/dedifferentiated 
liposarcomas, 3 of 48 (6%) of tumors exhibited NY-ESO-1 
expression. One showed positive staining in the well-
differentiated component and two in the dedifferentiated 
component. Of these three positive tumors, 1 was 
a primary presentation of a well differentiated/
dedifferentiated liposarcoma, and 2 were recurrent tumors. 
Two of these, a recurrent retroperitoneal tumor (patient 
#6 – well differentiated component only) and a primary 
leg tumor (patient #32 - dedifferentiated component only), 
exhibited 3+ intense staining in > 75% and > 25% of cells, 
respectively (Figure 1C and 1D). The third case was a 
recurrent groin dedifferentiated liposarcoma that showed 
weak (1+) yet diffuse (> 75% of tumor cells) staining 
(patient #64). (See Table 2) None of the pleomorphic 
liposarcomas revealed any NY-ESO-1 expression, nor did 
any of the benign lipomatous tumors or normal adipocytic 
tissue.
Peripheral nerve sheath tumors
Fourteen percent of MPNSTs expressed NY-ESO-1, 
mainly in spontaneous MPNST cases [4 of 26 (15%) 
spontaneous MPNSTs and 2 of 16 (12%) NF1-associated 
MPNSTs]. All four of the spontaneous MPNSTs and one 
of the NF1-associated tumors were primary neoplasms 
and the other NF-1 patient had a recurrent tumor. The 
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Table 1: NY-ESO immunohistochemical results 
  N NY-ESO-1 Positive (% of total)
Adipocytic Tumors   
 Myxoid/round cell LPS 13 13 (100%)
 Well-differentiated/Dedifferentiated LPS 48 3 (6%)
 Pleomorphic LPS 3 0 (0%)
 Lipoma 8 0 (0%)
 Myelolipoma 1 0 (0%)
Total 73 16 (22%)
Peripheral Nerve Sheath Tumors   
 Spontaneous MPNSTs 26 4 (15%)
 NF1-associated MPNSTs 16 2 (12%)
 Spontaneous NFs 22 0 (0%)
 NF1-associated NFs 13 0 (0%)
 Cellular Schwannoma 11 0 (0%)
Total 88 6 (7%)
Normal tissues   
 Nerve 18 0 (0%)
 Fat 3 0 (0%)
Figure 1: NY-ESO-1 immunohistochemical staining pattern and intensity in liposarcomas and MPNST. Primary myxoid/
round cell liposarcoma, H&E (A) and diffuse (> 75% of cells staining) 3+ IHC positivity (B). Dedifferentiated liposarcoma, H&E (C) and 
3+ IHC positivity in > 25% of cells (D). MPNST, H&E (E) and diffuse 3+ IHC positivity (F). Metastatic mxyoid/round cell liposarcoma, 
H&E (G) and diffuse 3+ IHC positivity (H). (200× magnification).
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Table 2: Characteristics of patients with positive NY-ESO-1 expression and staining pattern
Patient 
Number Tumor Type
Tumor 
Location
Tumor at 
Presentation
Neoadjuvant/
Adjuvant 
Therapy
NY-
ESO-1 
density
NY-ESO-1 
intensity
4 Myxoid LPS Thigh Recurrent no 3 3+
8 Myxoid LPS Gluteal Primary no 3 2+
10a Myxoid LPS Thigh Primary no 3 3+
10b Myxoid LPS Thigh Recurrent no 1 2+
14 Myxoid LPS Thigh Primary no 3 3+
17 Myxoid LPS with 5–10% round cell component Thigh Primary no 3 3+
26 Myxoid LPS Groin Metastatic yes 3 3+
29 Myxoid LPS with predominant round cell component Thigh Primary yes 3 3+
31 Myxoid LPS Gluteal Primary yes 3 3+
33a Myxoid LPS Thigh Primary no 2 3+
33b Myxoid LPS Abdomen Metastatic no 3 3+
46 Myxoid LPS Thigh Primary no 3 3+
54a Myxoid LPS Gluteal Primary no 3 3+
54b Myxoid LPS Shoulder Metastatic yes 3 3+
54c Myxoid LPS Paraspinal Metastatic yes 3 3+
71a Myxoid LPS Calf Primary no 3 2+
71b Myxoid LPS Epidural Metastatic yes 3 3+
71c Myxoid LPS Abdomen Metastatic yes 1 3+
71d Myxoid LPS Bone, T11-T12 Metastatic yes 3 3+
71e Myxoid LPS Sacrum Metastatic yes 2 3+
73 Myxoid LPS Thigh Primary yes 3 3+
6 DD LPS arising from WD LPS (only WD seen) Retroperitoneum Recurrent no 3 3+
32 DD LPS arising from WD LPS (only DD seen) Leg Primary no 2 3+
64 DD LPS Groin Recurrent yes 3 1+
105 sMPNST, high grade Leg Primary no 2 2–3+
109 sMPNST, high grade Thigh Primary no 1 1+
121 sMPNST, high grade Thigh Primary yes 3 3+
152 sMPNST, high grade Forearm Primary yes 3 3+
129 NF1- associated MPNST v. Post-XRT sarcoma Neck Recurrent yes 2 1+
110 NF1-MPNST, high grade Thigh Primary yes 3 3+
expression patterns of the MPNSTs were highly variable. 
Three of the spontaneous MPNSTs showed moderate to 
strong staining intensity (2–3+), with diffuse staining in most 
samples. (Table 2, Figure 1E and 1F) Only one spontaneous 
MPNST displayed weak (1+) and focal (< 25% of tumor 
cells) expression of NY-ESO-1. The two NF1 patients showed 
relatively diffuse tumoral staining (density score 2–3), but 
the intensity varied from weak (1+) in the recurrent tumor 
(patient #129) to strong (3+) in the primary thigh NF1-
MPNST. No spontaneous or NF-1 associated neurofibromas 
(0/35), schwannomas (0/11), or normal nerves expressed NY-
ESO-1.
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DISCUSSION
To our knowledge, this report significantly expands 
the PNSTs and well differentiated/dedifferentiated 
liposarcomas tested for NY-ESO-1, including a total of 42 
MPNSTs (both NF1-associated and sporadic tumors) and 
64 liposarcomas. It also is the first study to investigate NY-
ESO-1 immunostaining patterns in primary, recurrent, and 
metastatic myxoid/round cell liposarcomas.
Recently, Lai and colleagues demonstrated NY-ESO-1 
staining in 76% of synovial sarcomas, as well as positivity 
in limited numbers of other sarcomas including 2.9% (1/34) 
of MPNSTs and a single case (1/1) of dedifferentiated 
liposarcoma [12]. In their cohort, the striking prevalence of 
a strong and diffuse pattern of NY-ESO-1 staining (defined 
as 2–3+, > 50–70% of tumor cells) appeared to be confined 
to synovial sarcomas, prompting them to hypothesize that 
it may be a useful marker in the differential diagnosis 
with other spindle cell neoplasms [12]. However, in the 
current study, we evaluated a larger number of MPNSTs, 
both spontaneous and NF1-associated, and have shown 
that a higher percentage (14%) of MPNSTs displayed 
positivity, including 67% with intense (2−3+) staining 
than had been previously described. This result suggests 
caution in relying on NY-ESO-1 as a confirmatory stain 
to distinguish synovial sarcoma from other spindle cell 
neoplasm subtypes as Lai et al. suggested. 
Hemminger et al and Pollack et al. found NY-
ESO-1 to be very highly expressed in myxoid/round 
cell liposarcomas, with 89% and 100% expression, 
respectively [13, 14]. Indeed, this observation holds 
true in the current study, wherein we confirm 100% of 
myxoid/round cell liposarcoma cases showed moderate 
to strong (2–3+) staining for NY-ESO-1. Our study 
demonstrated, for the first time, that all recurrent and 
metastatic myxoid/round cell liposarcomas in our series 
retained their moderate to intense NY-ESO-1 expression 
pattern. Furthermore, three of these tumors continued to 
show strong positive staining following treatment with 
neoadjuvant chemotherapy. 
Our results also suggest possible new treatments 
for MPNST, well-differentiated liposarcoma and 
dedifferentiated liposarcoma, all of which respond poorly 
to existing chemoradiation therapies (6–10). Once patients 
with dedifferentiated liposarcoma develop non-visceral 
and visceral metastases, their median progression-free 
survival is 6.1 months and 3.3 months, respectively, and 
median overall survival 17.2 and 11.1 months, respectively 
[11] despite therapy. Recently NY-ESO-1 adoptive cellular 
therapy was granted orphan drug designation for synovial 
sarcomas and further confirmatory studies are ongoing 
[6, 15]. Future studies will be needed to determine if NY-
ESO-1 based immunotherapy shows clinical response 
in MPNST and well differentiated/dedifferentiated 
liposarcoma patients, and to identify the ideal histologies 
in which NY-ESO-1 immunotherapy may be particularly 
effective.
Murine models of MPNST and liposarcoma can 
provide a platform for the testing of novel therapies 
and further investigation of the potential of adoptive 
cell therapy in the treatment of sarcoma [16–21]. Guo 
et al. (2006) induced cancer testis antigen in three 
murine sarcoma cell lines in vitro, and in the MCA102 
derived murine xenograft model in vivo using 5-Aza-
2′-Deoxycytidine [22], suggesting that induction of 
cancer testis antigen may be possible in sarcoma patients 
whose tumors may not have robust expression of NY-
ESO-1. Immunogenic tumor-associated antigens, such 
as NY-ESO-1, that can be induced in sarcoma may be an 
effective means to break antigen-specific tolerance, which 
is a major barrier to immune-mediated cancer regression. 
This study highlights the potential of murine xenograft 
and transgenic models in the evaluation of adoptive cell 
therapy in MPNST and liposarcoma. 
The enthusiasm around NY-ESO-1 as a potential 
immunotherapeutic target is not unfounded. Previous 
testing of immunotherapy regimens generally have 
shown objective tumor regression in up to 72% of 
patients with metastatic melanoma who received in-
vitro cultured melanoma-reactive T cells [23, 24]. 
Table 3: Comparison of changes in expression patterns of primary, locally recurrent, and 
metastatic tumors
Patient 
Number Tumor Type Tumor 
Location of Tumor 
Recurrence/
Metastasis
Staining Density 
Changes
Staining Intensity 
Changes
10 Myxoid LPS Primary → Recurrent Thigh Decreased (3 → 1) Decreased (3+ → 2+) 
54 Myxoid LPS Primary → Metastatic Shoulder Unchanged (3 → 3) Unchanged (3+ → 3+)
Myxoid LPS Primary → Metastatic Paraspinal Unchanged (3 → 3) Unchanged (3+ → 3+)
71 Myxoid LPS Primary → Metastatic Epidural Unchanged (3 → 3) Increased (2+ → 3+)
Myxoid LPS Primary → Metastatic Abdomen Decreased (3 → 1) Increased (2+ → 3+)
Myxoid LPS Primary → Metastatic Bone, T11-T12 Unchanged (3 → 3) Increased (2+ → 3+)
Myxoid LPS Primary → Metastatic Sacrum Decreased (3 → 2) Increased (2+ → 3+)
33 Myxoid LPS Primary → Metastatic Abdomen Increased (2 → 3) Unchanged (3+ → 3+)
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Recently, Robbins and colleagues used genetically 
engineered lymphocytes reactive for NY-ESO-1 in 17 
patients with synovial sarcomas and melanomas that 
were immunohistochemically positive for NY-ESO-1; 
they demonstrated significant tumor regression in 4 of 6 
patients (67%) with synovial sarcoma and 5 of 11 patients 
(45%) with melanoma. This included objective clinical 
responses in patients with progressive disease and tumors 
previously refractory to conventional therapy. Sustained 
partial response was noted in one of the patients with 
synovial sarcoma and complete regression was seen in 
two patients with melanoma [6]. With growing evidence 
of diffuse and strong expression of NY-ESO-1 in myxoid/
round cell liposarcoma, as well as expression in a subset 
of MPNSTs and well differentiated/dedifferentiated 
liposarcoma, it certainly provides further support for 
extending clinical trials to patients with sarcomas 
that express NY-ESO-1 [14]. Furthermore, adoptive 
immunotherapy targeting NY-ESO-1 appears to be quite 
well tolerated, with side effects attributable mainly to the 
preconditioning regimen [6, 25]. 
We corroborate the finding that NY-ESO-1 staining is 
limited to malignant neoplasms and testis [25, 26] and does 
not appear to be expressed in other normal adult tissues. 
We also did not find any staining in benign neoplasms, 
including schwannomas, neurofibromas (spontaneous or 
NF-1 associated), lipomas, or myelolipomas. 
A limitation of this study is the small sample size 
for the patients (n = 4) with multiple recurrent/metastatic 
myxoid/round cell liposarcoma tumors (a total of 
12 separate primary, recurrent, and metastatic tumors). 
However, the remarkably consistent finding of intense 
immunopositivity in all the cases of myxoid/round cell 
liposarcoma is compelling and warrants validation with 
additional studies.
In summary, this is the first report of strong consistent 
staining in multiple metastatic and recurrent myxoid/round 
cell liposarcoma. This study also significantly expands 
the total number of well-differentiated/dedifferentiated 
liposarcomas and MPNSTs (both NF-1 associated and 
sporadic) tested and is the first report of staining in a well 
differentiated liposarcoma. Our results suggest that NY-
ESO-1 targeted immunotherapy may benefit patients with 
metastatic and recurrent myxoid/round cell liposarcoma. 
Additionally, a proportion of patients with MPNSTs and 
well differentiated/dedifferentiated liposarcomas tumor 
types with historically poor response to chemoradiation 
may also benefit from NY-ESO-1 targeted immunotherapy. 
Further clinical trials will help establish the effectiveness 
of this therapeutic approach in these tumor types.
MATERIALS AND METHODS
The study was approved by the University of 
California at Los Angeles Institutional Review Board. 
Two tissue microarrays (TMA) were constructed at our 
institution, one with samples of benign and malignant 
PNSTs and normal nerve and the other with different types 
of adipocytic tumors and normal adipocytic tissue. Prior 
to TMA construction, all original cases, as well as any 
prior or subsequent local recurrences and metastases, were 
reviewed to confirm the diagnosis by a pathologist with 
expertise in soft tissue tumors (SD). The comprehensive 
PNST TMA was constructed from 106 patient 
samples, including 26 spontaneous MPNSTs, 16 NF1-
associated MPNSTs, 22 spontaneous neurofibromas, 13 
neurofibromas arising in patients with diagnosed NF-
1, 11 spontaneous schwannomas, and 18 samples of 
normal nerve. The adipocytic TMA was comprised of 
well-differentiated/dedifferentiated liposarcoma (n = 48), 
myxoid/round cell liposarcoma (n = 13), pleomorphic 
liposarcoma (n = 3), lipomas (n = 8), myelolipoma (n = 1), 
and normal adipocytic tissue (n = 3). Dedifferentiated 
liposarcomas were diagnosed using the criteria of Evans 
[27]. Both TMAs contained primary, locally recurrent 
and metastatic malignant tumors; 9 MPNST and 20 
liposarcoma patients had samples drawn from their 
primary and/or recurrent tumor, and then later developed 
locally recurrent and/or metastatic disease which were 
also sampled and used in the TMAs. Patients were treated 
with neoadjuvant or adjuvant chemotherapy according 
to NCCN guidelines (Table 2) [28]. Each sample had 
triplicate core samples to account for tumor heterogeneity. 
Each TMA was stained with hematoxylin and eosin 
stain for morphologic evaluation, as well as NY-ESO-1 
immunoperoxidase for immunohistochemical (IHC) 
scoring. Affinity-purified mouse monoclonal antibody 
against NY-ESO-1, clone E978 (Sigma- Aldrich, N2038) 
was used on slides obtained from human FFPE samples, 
guide dilution of 1:300, and incubated at 4°C overnight. 
Biotinylated anti-mouse IgG (H+L) antibody (Vector 
Laboratory, BA-9200) and Horseradish Peroxidase Avidin 
D (Vector Laboratory, A-2004) were used as Streptavidin-
biotin-peroxidase complex (SABC) technique for 
immunohistochemical staining. Slides were developed 
in DAB substrate and counterstained with Hematoxylin. 
Citrate buffer (pH 6.0) for antigen retrieval was used and 
steamed at 100°C for 30 minutes. NY-ESO-1 staining of 
tumor cells was scored according to intensity (weak, 1+; 
moderate, 2+; strong, 3+) and density (1 = 1–25% of tumor 
cells; 2 = 26–75%; and 3 = > 75%). Examining both tumor 
intensity and density characterizes tumor samples with 
low tumor cell density with edematous hyalinized tissue, 
coagulative necrosis, reactive matrix, and weak NY-ESO-1 
staining below the intensity required to label the tumor as 
positive, as can be seen in post-neoadjuvant treated tumor 
samples. Cores were doubly scored by two pathologists 
(M V-L and SD) who were blinded to the diagnosis and 
tumor status (primary, recurrence, metastatic). 
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